依达拉奉联合纤溶酶治疗急性脑梗死的临床研究  

Edaravone combined with fibrinogenase in treatment of acute cerebral infarction

作　　者：王展航[1] 覃士明[1] 贾兰[1] 樊哲江[1] 

机构地区：[1]广州中医药大学祈福医院脑病中心,511495

出　　处：《中华神经医学杂志》2006年第7期726-727,共2页Chinese Journal of Neuromedicine

摘　　要：目的观察依达拉奉联合纤溶酶治疗急性脑梗死的疗效和安全性。方法对37例急性脑梗死患者给予依达拉奉(必存)联合纤溶酶治疗,并与应用纤溶酶和香丹治疗的38例患者进行治疗前后欧洲脑卒中量表(ESS)、血浆纤维蛋白原(FIB)含量变化和日常生活能力(ADL)比较。结果治疗后依达拉奉组和香丹组ESS评分均有改善(P＜0．05),但依达拉奉组改善更明显,且与香丹组有显著性差异(P＜0．05)；两组FIB水平较治疗前明显降低(P＜0．01)；两组ADL水平均较治疗前上升(P＜0．01),但依达拉奉组上升更明显,且与香丹组有显著性差异(P＜0．05)。结论依达拉奉联合纤溶酶治疗急性脑梗死能有效改善神经功能,安全性高。Objective To observe the efficacy and safety of edaravone combined with fibrinogenase in treatment of acute cerebral infarction. Methods 37 patients with acute cerebral infarction were treated by edaravone combined with fibrinogenase, and another 38 controls were treated by Xiangdan with fibrinogenase. ESS, ADL and FIB content change in two groups were assessed at different point before treatment and two weeks after treatment. Results The scores by ESS in the two groups were increased after treatment, but that in the edaravone group was dramatically, showing significant different from that in the xiangdan group （P〈0.05）. FIB of the two groups was significantly lowered after treatment （P〈0.01） and ADL of the two groups improved after treatment （P〈0.01）, but the increase in the edaravone group was significant compared to the xiangdan group （P〈0.05）. Conclusion Edaravone combined with fibrinogenase is effective and safe in treatment of acute cerebral infarction.

关 键 词：依达拉奉 纤溶酶 急性脑梗死 

分 类 号：R743.32[医药卫生—神经病学与精神病学]